$3.84
4.48% yesterday
Nasdaq, Oct 15, 10:00 pm CET
ISIN
US09071M1062
Symbol
BLRX

Bioline RX Ltd Sponsored ADR Stock price

$3.84
+0.09 2.40% 1M
+1.02 36.16% 6M
-4.72 55.14% YTD
-13.66 78.06% 1Y
-28.97 88.30% 3Y
-59.36 93.92% 5Y
-860.16 99.56% 10Y
-3,350.16 99.89% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
-0.18 4.48%
ISIN
US09071M1062
Symbol
BLRX
Industry

Key metrics

Basic
Market capitalization
$17.5m
Enterprise Value
$1.9m
Net debt
positive
Cash
$28.2m
Shares outstanding
2.6b
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.0 | 7.0
EV/Sales
0.1 | 2.1
EV/FCF
negative
P/B
0.9
Financial Health
Equity Ratio
34.6%
Return on Equity
-68.5%
ROCE
-52.2%
ROIC
-
Debt/Equity
0.6
Financials (TTM | estimate)
Revenue
$17.3m | $2.6m
EBITDA
$-11.5m | $-10.4m
EBIT
$-14.5m | -
Net Income
$-7.8m | $-22.3m
Free Cash Flow
$-21.2m
Growth (TTM | estimate)
Revenue
1.2% | -91.1%
EBITDA
70.8% | 44.2%
EBIT
65.1% | -
Net Income
74.0% | -142.2%
Free Cash Flow
30.4%
Margin (TTM | estimate)
Gross
59.3%
EBITDA
-66.5% | -402.5%
EBIT
-84.1%
Net
-45.3% | -864.1%
Free Cash Flow
-122.9%
More
EPS
$0.0
FCF per Share
$0.0
Short interest
4.5%
Employees
-
Rev per Employee
-
Show more

Is Bioline RX Ltd Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

Financial data from Bioline RX Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
17 17
1% 1%
100%
- Direct Costs 7.02 7.02
16% 16%
41%
10 10
7% 7%
59%
- Selling and Administrative Expenses 15 15
56% 56%
89%
- Research and Development Expense 8.38 8.38
21% 21%
49%
-11 -11
71% 71%
-66%
- Depreciation and Amortization 3.03 3.03
32% 32%
18%
EBIT (Operating Income) EBIT -15 -15
65% 65%
-84%
Net Profit -7.82 -7.82
74% 74%
-45%

In millions USD.

Don't miss a Thing! We will send you all news about Bioline RX Ltd Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Bioline RX Ltd Sponsored ADR Stock News

Neutral
Seeking Alpha
17 days ago
BioLineRx Ltd. - Special Call Company Participants Irina Koffler - Managing Director Philip Serlin - Chief Executive Officer Ella Sorani - Chief Development Officer Conference Call Participants Joseph Pantginis - H.C.
Neutral
PRNewsWire
17 days ago
- GLIX1 restores TET2 activity in cancer, resulting in double stranded DNA breaks in cancer cells only - - FDA IND clearance received for Phase 1/2a study, expected to initiate in Q1 2026 - - Glioblastoma market opportunity estimated to be in excess of $3.8 billion annually across the US and EU5 by 2030 - - BioLineRx affirms its cash runway into the first half of 2027 - - Management to host con...
Neutral
Seeking Alpha
2 months ago
BioLineRx Ltd. (NASDAQ:BLRX ) Q2 2025 Earnings Conference Call August 14, 2025 8:30 AM ET Company Participants Irina Koffler - Corporate Participant Mali Zeevi - Chief Financial Officer Philip A.
More Bioline RX Ltd Sponsored ADR News

Company Profile

BioLineRx Ltd. is a clinical stage biopharmaceutical company focused on oncology. The company was founded in April 2003 and is headquartered in Modi'in, Israel.

Head office Israel
CEO Mr. Serlin
Founded 2003
Website www.biolinerx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today